BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 23335532)

  • 21. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer?
    van der Leest C; Smit EF; Baas J; Versteijlen RJ; van Walree N; Hoogsteden HC; Aerts JG
    Lung Cancer; 2012 Apr; 76(1):67-71. PubMed ID: 21996089
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of primary fluorine-18 fluorodeoxyglucose standard uptake value for a better choice of systematic nodal dissection or sampling in clinical stage ia non--small-cell lung cancer.
    Li X; Zhang H; Xing L; Xu X; Xie P; Ma H; Zhang L; Chen M; Sun X; Xu W; Chen L; Yu J
    Clin Lung Cancer; 2013 Sep; 14(5):568-73. PubMed ID: 23835164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases.
    Billè A; Okiror L; Skanjeti A; Errico L; Arena V; Penna D; Ardissone F; Pelosi E
    Clin Lung Cancer; 2013 Mar; 14(2):149-56. PubMed ID: 22682667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
    Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
    J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with first-line cisplatin-based chemotherapy: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Karakus A; Isikdogan A
    J BUON; 2012; 17(3):533-6. PubMed ID: 23033295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
    Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
    Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
    Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H
    Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer.
    Abe K; Baba S; Kaneko K; Isoda T; Yabuuchi H; Sasaki M; Sakai S; Yoshino I; Honda H
    Clin Imaging; 2009; 33(2):90-5. PubMed ID: 19237050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
    Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
    Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COV is a readily available quantitative indicator of metabolic heterogeneity for predicting survival of patients with early and locally advanced NSCLC manifesting as central lung cancer.
    Yu T
    Eur J Radiol; 2020 Nov; 132():109338. PubMed ID: 33068840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of 18-FDG uptake in early stage NSCLC.
    Chen JC; Huang TW; Cheng YL; Chang H; Tzao C; Huang WS; Lee SC
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):413-6. PubMed ID: 19795329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and central photopenia detected by fluorine-18 fluoro-deoxy-glucose positron emission tomography (FDG-PET) in patients with locoregional non-small cell lung cancer treated with radiotherapy.
    Ashley Cox R; Akhurst T; Bressel M; MacManus M; Ball D
    Radiother Oncol; 2017 Jul; 124(1):25-30. PubMed ID: 28662870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
    Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
    Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy.
    Burdick MJ; Stephans KL; Reddy CA; Djemil T; Srinivas SM; Videtic GM
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1033-9. PubMed ID: 20472359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.